Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 2/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24829447 | 0.92 | CALCRL (0.51) | CALCRLSSTR3HDAC1FAPMMP3 | |
| SCHEMBL23330068 | 0.92 | CALCRL (0.51) | CALCRLSSTR3HDAC1FAPMMP3 | |
| SCHEMBL22910386 | 0.90 | CALCRL (0.51) | CALCRLSSTR3HDAC1FAPMMP3 | |
| SCHEMBL24164777 | 0.89 | CALCRL (0.50) | CALCRLSSTR3HDAC1FAPF2 | |
| SCHEMBL24829565 | 0.88 | CALCRL (0.49) | CALCRLSSTR3HDAC1FAPMMP3 | |
| SCHEMBL27058431 | 0.88 | CALCRL (0.55) | CALCRLSSTR3HRH1F2 | |
| SCHEMBL23286123 | 0.83 | CALCRL (0.52) | CALCRLSSTR3HDAC1 | |
| SCHEMBL23347260 | 0.82 | CALCRL (0.47) | CALCRLSSTR3HDAC1MMP3HRH1 | |
| SCHEMBL24829473 | 0.81 | SSTR3 (0.57) | CALCRLSSTR3SIRT2SIRT1SIRT3 | |
| SCHEMBL21065668 | 0.81 | FAP (0.42) | CALCRLFAPSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ACVR1 | CALCRL 4173/4885SSTR3 2097/4885HDAC1 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.